
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
created: Oct. 20, 2025, 8 a.m. | updated: Oct. 20, 2025, 1:52 p.m.
Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of historical fact are forward-looking statements.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements.
Forward-looking statements contained in this news release are made as of this date.
6 hours, 18 minutes ago: News Ticker - markets.businessinsider.com